

# NYRx Brand Less Than Generic Program Update

---

## What Pharmacy Providers and Prescribers Need to Know

Effective **November 21, 2024**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Forteo®**, **Sandostatin LAR®**, **Sprycel®**, and **Zavesca®** will be **ADDED** to the program.
- **Kombiglyze® XR**, **Nascobal®**, and **Vascepa®** will be **REMOVED** from the program.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form, and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the least expensive alternative for the patient. Brand name drugs included in this program:

- Do not require "Dispense as Written" (DAW) or "Brand Medically Necessary" on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

## Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of a DAW Product Selection Code of "1"; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive an NCPDP reject response of "22" which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this is DAW code "1" and "Brand Medically Necessary" on the prescription.

For a complete list, see [NYRx Brand Less Than Generic Drugs](#) on the next page.



# NYRx Brand Less Than Generic Drugs

List of Brand Name Drugs included in this program**		
Advair Diskus®	<b>Forteo®</b>	<b>Sandostatin LAR®</b>
Advair HFA®	Glumetza®	<b>Sprycel®</b>
Alphagan P® 0.15%	Istalol®	Spiriva® Handihaler®
Alphagan P® 0.1%	Kitabis® Pak	Symbicort®
Apriso®	Myrbetriq®	Tegretol® suspension
Azopt™	Nexavar®	Tegretol® XR
Bethkis®	NuvaRing®	Trileptal® suspension
Carbaglu®	Onglyza®	Ventolin® HFA
CellCept® suspension	Oseni®	Victoza®
Combigan®	Pentasa®	Votrient®
Copaxone® 20 mg SQ	Pradaxa®	Vyvanse® capsules
Daytrana®	Protonix® suspension	Xigduo® XR
Depakote® Sprinkle	Pylera®	Xopenex HFA®
Dymista®	Restasis®	<b>Zavesca®</b>
EpiPen	Retin-A® cream	Zegerid® Rx
EpiPen, Jr	Risperdal Consta®	
Farxiga®	Ritalin LA®	

- \* This list is subject to change. For the most recent updates, see the [Brand Less Than Generic Program Updates](#).
- \* Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

## Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)

## Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at [NYRxEO@primetherapeutics.com](mailto:NYRxEO@primetherapeutics.com) from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.